A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More
At the American Heart Association Scientific Sessions 2011, Dr. John Mandrola presented a poster on gender-specific results of atrial fibrillation ablation in a private practice setting. In this video interview with him about the poster, he mentioned that in his experience women appear to be more challenging to treat with atrial fibrillation ablation and do …
Read More
Recently StopAfib.org partnered with the Cleveland Clinic to give you an opportunity to chat live with two of their atrial fibrillation experts, Dr. Walid Saliba and Dr. David Van Wagoner, who were joined by StopAfib.org founder Mellanie True Hills. The transcript of our afib community chat with these atrial fibrillation experts from the Cleveland Clinic …
Read More
An FDA advisory panel voted that the overall benefits outweighed the risks in afib ablations using the AtriCure Synergy bipolar radiofrequency clamp. This was based on the results of the ABLATE clinical trial for ablation of persistent or longstanding persistent atrial fibrillation during other heart surgery. The panel recommended that the FDA approve it, setting …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More